Análisis de impacto presupuestal de las terapias combinadas bosentan + sildenafil, ambrisentan + tadalafil e iloprost + bosentan en pacientes diagnosticados con hipertensión pulmonar grupo 1 (HAPG1 idiopática-HAPI y asociada-HAPA) de clase funcional II, I

Romano Gómez, Giancarlo; Ávila Reina, Adriana; Díaz Ortega, Miguel Hernando.
Bogotá; IETS; mayo 2016. 36 p. tab.
Monografia em Espanhol | BRISA, LILACS | ID: biblio-846825

Documentos relacionados

  1. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
  2. Adjunct ambrisentan therapy had clinical benefits in 5 dogs with sildenafil-refractory pulmonary hypertension.
  3. [Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia].
  4. Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.
  5. PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.
  6. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
  7. Inhibidores de fosfodiesterasa-5 para el tratamiento de la hipertensión arterial pulmonar
  8. Phosphodiesterase-5 inhibitors in pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
  9. Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis.
  10. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.